JPRN-jRCT2080223280已完成3 期
Extension Study of JR-051 for Patients with Fabry Disease
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- •Subjects who have participated in the previous study (Evaluation Study to Pharmacodynamic Effects of JR-051 for Patients with Fabry Disease (Protocol number: JR-051-301) and have completed the 52-week study visit, but for whom the principal investigator or the subinvestigator judges that there is no concern about shifting to the extension study in terms of the safety.
排除标准
- •Individuals with severe pulmonary, hepatic, cardiac, or renal dysfunction (except for dysfunction associated with the progression of Fabry disease)
研究者
相似试验
进行中（未招募）
1 期
An Extension Study of JR-171-101 Study in Patients With Mucopolysaccharidosis Type IMucopolysaccharidosis IJPRN-jRCT2051210040Kawashima Satoshi14
未知
2 期
Phase II Study of S-555739 in Patients with Japanese Cedar Pollinosis in an Environmental Challenge ChamberJPRN-jRCT2080221936SHIONOGI & CO., LTD.
已完成
1 期
A Phase I/II study of JR-031 for the patients of standard primary treatment-refractory acute graft-versus-host disease (acute GVHD) after hematopoietic stem cell transplantatioStandard primary treatment-refractory acute GVHDJPRN-UMIN000001716JCR pharmaceuticals Co.,Ltd20
进行中（未招募）
1 期
An extension study of JR-031 in infants with neonatal hypoxic ischemic encephalopathy (hereinafter referred to as nHIE) for which hypothermia therapy is indicatedneonatal hypoxic ischemic encephalopathy (nHIE)JPRN-jRCT2033200293Yamamoto Tatsuyoshi13
未知
3 期
Phase III study of AJG511 in patients with active ulcerative colitisulcerative colitisJPRN-jRCT2080222653EA Pharma Co.,Ltd.120